$COSM: Insider Buying + $40M Revenue and Robotic Expansion catalyst!

Is nobody watching the tape on $COSM (Cosmos Health) today? While the broader market is chasing ghosts, the CEO just put his money where his mouth is, and the company just dropped a massive operational update that the algorithms haven't fully priced in yet. Today’s News: The "$40M Revenue" Catalyst: Cosmos Health just announced a massive expansion at Cosmofarm (their pharma distribution arm). Here’s why the "smart money" is paying attention: • Robotic Expansion: They are deploying advanced AI/robotic systems to support an additional $40M in annual revenue. • Unit Economics: Revenue per customer is up 12% and profitability per customer is up 14%. They aren't just growing; they’re getting leaner and meaner. • Massive Price Target: Zacks Small-Cap Research recently initiated coverage with a $4.50 valuation. With the stock trading around $0.50–$0.60, we are talking about a potential 8x return if they hit that target. The Lead: CEO is Gobbling Up Shares: Look at the Form 4s. CEO Grigorios Siokas has been on an absolute tear, accumulating millions of shares. • The Latest: He just picked up another 493,495 shares (valued at \~$220k) via a debt exchange. • The Context: This isn’t a one-off. He has increased his stake by millions of shares since 2025 started. When a CEO swaps company debt for equity at these levels, they aren't looking for a 5% swing—they’re looking for a moonshot. Why Now? 1. Undervalued: Market cap is sitting under $25M despite $50M+ in annual sales. 2. Nasdaq Compliance: They are fighting to stay above $1.00, and with this much insider buying, management clearly thinks the organic value is well above the current price. 3. Volume is Spiking: We're seeing "unusual volume" alerts today. Usually, the volume precedes the massive breakout. The setup is clear: Massive insider skin in the game + $40M revenue expansion + a price target that’s lightyears away from current levels.